Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Your donations help support people living with type 1 diabetes today and fund the best treatment and cure research, no matter where in the world it takes place.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
Join our Virtual Triathlon Challenge and swim, cycle and run while raising money to fund Breakthrough T1D’s life-changing type 1 research.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF has now rebranded to Breakthrough T1D. Our name has changed, our mission has not.
Home > News & events > News > Breakthrough in T1D treatment: Engineered islets produce insulin without immunosuppression
Islets are clusters of cells in the pancreas, with beta cells within these islets responsible for producing insulin. In T1D, the immune system attacks and destroys these insulin-producing cells. To combat this, Sana’s trial used islets from deceased donors, which were genetically modified using the company’s ‘hypoimmune’ technology to avoid immune system rejection. These modified islets were then implanted into the muscle tissue of a person with T1D who had volunteered to be part of the study.
After just four weeks, the research team could tell that the person was making significantly more insulin than before, by measuring their C-peptide levels – an important marker of insulin production. This confirmed that the transplanted islets were alive, functioning, and producing insulin. Critically, this was achieved without the need for immunosuppressive drugs. This marks the first time that engineered islets have successfully avoided immune destruction.
The data that has been released is the first step in this incredibly promising research programme.
Current cell therapy options using donor islets are limited by the scarcity of donor organs and the ongoing reliance on immunosuppressive drugs, which can have serious side effects. The application of hypoimmune technology could change this, providing a way to protect insulin-producing cells without such drugs.
While this represents an important breakthrough, islets from organ donors are in short supply. Stem cell-derived islets could offer a more scalable solution for treating a larger number of people with T1D. Today’s results provide hope that using hypoimmune technology with stem cell-derived islets could lead to the development of immune-evasive, insulin-producing cells that are more widely available.
Progress will take significant time, effort, and money. Thanks to your support, every day we take another step toward a possible life-changing T1D cure.
At Breakthrough T1D, we are proud to have supported this promising research by investing in Sana Biotechnology through the T1D Fund. Their innovative hypoimmune engineering technology holds great potential for developing stem cell-based treatments that do not require broad immunosuppressive drugs. We look forward to seeing the continued progress of this trial.
Rachel Connor, Director of Research Partnerships says: “Today’s breakthrough offers the tantalising prospect of insulin-producing, immune-evasive cells for many more people living with T1D. Eliminating the need for immunosuppressive drugs makes a significant stride toward making cell therapies that allow people with T1D to make their own insulin again accessible to all. At Breakthrough T1D, we’re thrilled to support research that brings us closer to life changing cures for T1D.”
Find out about the global research we're funding to find cures and better treatments for T1D.
Get information and advice about living well with type 1.
Join our mission to find cures for T1D and, until then, make life better for people living with it.
Our highlights from a year full of breakthroughs in type 1 diabetes research and advocacy.
The framework aims to encourage UK researchers to consider different sexes (biological attributes) and genders (roles, behaviours and identity in society) to address gaps in health data.
Our Access for All report, launched today, highlights how far we’ve come with advancements in diabetes technology, but shows that many people still face barriers when trying to access T1D technology.
New international guidance detailing how to monitor and support people with early-stage type 1 diabetes (T1D) has the potential to reduce the trauma associated with being diagnosed with T1D, enable people to access the latest treatments to delay the need for insulin therapy, and reduce long-term health complications.
Immunotherapy, beta cell replacement, smart insulins – we’re driving research in the most promising areas to find cures and better treatments for type 1 diabetes.
